Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
16.19
0.00 (0.00%)
Dec 3, 2024, 4:00 PM EST - Market closed
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of 188.96M AUD in the quarter ending June 30, 2024, with 58.05% growth. This brings the company's revenue in the last twelve months to 645.68M, up 80.92% year-over-year. In the year 2023, Telix Pharmaceuticals had annual revenue of 502.55M with 213.90% growth.
Revenue (ttm)
645.68M AUD
Revenue Growth
+80.92%
P/S Ratio
n/a
Revenue / Employee
1,555,848 AUD
Employees
415
Market Cap
5.36B undefined
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Grifols | 7.81B |
Stevanato Group | 1.22B |
Waystar Holding | 906.14M |
Ionis Pharmaceuticals | 803.07M |
Inspire Medical Systems | 755.59M |
Krystal Biotech | 241.52M |
BridgeBio Pharma | 217.77M |
PROCEPT BioRobotics | 199.84M |
TLX News
- 15 days ago - Telix to Add FAP-Targeting Candidates to Theranostic Pipeline - GlobeNewsWire
- 20 days ago - Telix ADSs Commence Trading on Nasdaq - GlobeNewsWire